<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00654485</url>
  </required_header>
  <id_info>
    <org_study_id>4522IL/0069</org_study_id>
    <secondary_id>D3560C00069</secondary_id>
    <nct_id>NCT00654485</nct_id>
  </id_info>
  <brief_title>COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects</brief_title>
  <official_title>A 12 Week Randomized, Double-Blind, Force-Titration, Parallel Group, Multi Centre, Phase IIIb Study to Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects With Raised LDL-C and a 10 Year Risk of CHD &gt;10%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of treatment with rosuvastatin with
      atorvastatin in reducing Low density lipoprotein cholesterol over 6 weeks of treatment in
      subjects with metabolic syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Low density lipoprotein cholesterol levels following treatment in subjects with metabolic syndrome.</measure>
    <time_frame>At 6 &amp; 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modification of other lipids and lipoproteins</measure>
    <time_frame>At 6 &amp; 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modification of insulin resistance, inflammatory markers &amp; glucose metabolism</measure>
    <time_frame>At 6 &amp; 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: adverse events &amp; abnormal laboratory markers</measure>
    <time_frame>At 6 &amp; 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">940</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <arm_group_label>1</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <arm_group_label>2</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of 3 or more coronary heart disease risk factors as defined by the protocol.

          -  Fasting low density lipoprotein cholesterol level of &gt; 130 mg/dL.

          -  Documented history of, or high risk of coronary heart disease or other established
             atherosclerotic disease.

          -  Not previously taken statins.

        Exclusion Criteria:

          -  The use of lipid lowering drugs or dietary supplements after Visit 1

          -  Active arterial disease eg Unstable angina, or recent arterial surgery

          -  Blood lipid levels above the limits defined in the protocol

          -  Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Anton Stalenhoef</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Centre, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Russell Esterline</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2008</study_first_submitted>
  <study_first_submitted_qc>April 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2008</study_first_posted>
  <last_update_submitted>March 13, 2009</last_update_submitted>
  <last_update_submitted_qc>March 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2009</last_update_posted>
  <keyword>Cholesterol</keyword>
  <keyword>hypercholesterolemia</keyword>
  <keyword>low density lipoproteins</keyword>
  <keyword>metabolic syndrome</keyword>
  <keyword>Rosuvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

